CIK 0001439222 · Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-02-13 | Bowden Christopher Chief Medical Officer | Option exercise | +7,100 | $35.16 | $250K | 8,750 |
| 2020-02-13 | Bowden Christopher Chief Medical Officer | Sale | −7,100 | $50.16 | $356K | 1,650 |
| 2020-02-13 | Bowden Christopher Chief Medical Officer | Option exercise · Stock option (right to buy) | −7,100 | 19,306 | ||
| 2020-02-11 | Bowden Christopher Chief Medical Officer | Option exercise | +621 | $35.16 | $22K | 2,271 |
| 2020-02-11 | Bowden Christopher Chief Medical Officer | Sale | −621 | $50.02 | $31K | 1,650 |
| 2020-02-11 | Bowden Christopher Chief Medical Officer | Option exercise · Stock option (right to buy) | −621 | 26,406 | ||
| 2020-02-05 | Bowden Christopher Chief Medical Officer | Option exercise | +35,447 | $35.16 | $1.2M | 37,097 |
| 2020-02-05 | Bowden Christopher Chief Medical Officer | Option exercise · Stock option (right to buy) | −35,447 | 27,027 | ||
| 2020-02-04 | Bowden Christopher Chief Medical Officer | Option exercise | +8,526 | $35.16 | $300K | 15,841 |
| 2020-02-04 | Bowden Christopher Chief Medical Officer | Sale | −14,191 | $50.03 | $710K | 1,650 |
| 2020-02-04 | Bowden Christopher Chief Medical Officer | Sale | −35,447 | $50.10 | $1.8M | 1,650 |
| 2020-02-04 | Bowden Christopher Chief Medical Officer | Option exercise · Stock option (right to buy) | −8,526 | 62,474 | ||
| 2020-01-06 | Car Bruce Chief Scientific Officer | Grant or award · Stock option (right to buy) | +47,007 | 47,007 | ||
| 2020-01-06 | Car Bruce Chief Scientific Officer | Grant or award · Restricted stock units | +10,311 | 10,311 | ||
| 2019-12-26 | Alenson Carman Principal Accounting Officer | Sale | −2,950 | $50.09 | $148K | 184 |
| 2019-12-03 | Biller Jonathan Chief Legal Officer | Grant or award · Stock option (right to buy) | +78,824 | 78,824 | ||
| 2019-12-03 | Biller Jonathan Chief Legal Officer | Grant or award · Restricted stock units | +17,259 | 17,259 | ||
| 2019-11-13 | FOUSE JACQUALYN A Chief Executive Officer | Purchase | +40,322 | $31.00 | $1.2M | 41,722 |
| 2019-11-13 | Schenkein David P Director | Purchase | +8,064 | $31.00 | $250K | 97,567 |
| 2019-11-12 | CELGENE CORP /DE/ 10% owner | Purchase | +403,225 | $31.00 | $12.5M | 1,777,824 |
Page 50 of 63 · 1,252 trades